FDA has approved the latest version of Abbott’s MitraClip, the G4. Intended to treat mitral regurgitation, the minimally invasive next-gen heart valve repair device offers four clip sizes with a wider grasping area and an alternative leaflet grasping feature (Controlled Gripper Actuation). The device also provides real-time left atrial pressure monitoring during implantation, which helps doctors monitor and confirm reduction of mitral regurgitation during the procedure—this aids in helping the doctor decide whether the MitraClip should be repositioned.
“With the fourth generation of MitraClip, we set out to build a system that would help physicians individualize the therapy to each patient and deliver even more features that can treat both primary and secondary mitral regurgitation,” said Neil Moat, M.D., chief medical officer of Abbott’s structural heart business, in a company press release.
Abbott’s MitraClip has been available to patients in the United States since 2013.
Related Articles
-
Results from the AVEIR DR i2i Investigational Device Exemption (IDE) study through three-months post-implant showed a 98.3% implant success rate for physicians and more than 97% of people had a successful atrio-ventricular synchrony, so that the upper and lower chamber…
-
Effective February 7, the agency will conduct inspections across all commodities, as well as mission-critical foreign and domestic inspections.
-
The draft guidance proposes updates to clarify how the Breakthrough Devices Program may be applicable to certain medical devices that promote health equity, as well as considerations in designating eligible devices that may benefit populations impacted by disparities in health…
-
As of June 1, 2022, the Center for Devices and Radiological Health plans to accept all non-COVID in vitro diagnostic (IVD) pre-submissions.
